London Healthcare Conference
November 15, 2017 at 10:40am GMT
Evercore ISI Biopharma Catalyst/Deep Dive Conference
November 30, 2017 at 3:30pm ET
A webcast of each presentation will be accessible through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location for approximately two weeks.
ImmunoGen is a clinical-stage biotechnology company that develops
targeted cancer therapeutics using its proprietary ADC technology. The
Company's lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in a Phase 1b/2 trial in combination regimens for earlier-stage disease.
ImmunoGen has three additional clinical-stage product candidates, two of
which are being developed in collaboration with Jazz Pharmaceuticals.
ImmunoGen's ADC technology is also used in Roche's marketed product,
Kadcyla®, and in programs in development by Amgen, Bayer,
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Transition Report on Form 10-K for the fiscal year ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.
Courtney O'Konek, 781-895-0600
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
News Provided by Acquire Media